Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial

Clinical Therapeutics

Volumn 30, Issue 11, 2008, Pages 1988-2004

  Clauw, Daniel J ^a   Mease, Philip ^b   Palmer, Robert H ^c   Gendreau, R Michael ^d   Wang, Yong ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Seattle Rhumatology Associates   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d Cypress Bioscience Inc   (United States)

Author keywords

fatigue; fibromyalgia; milnacipran; pain; physical function

Indexed keywords

MILNACIPRAN; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; CAPSULES; CONSTIPATION; CYCLOPROPANES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PATIENT SATISFACTION; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 57649234533     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.11.009     Document Type: Article

References (55)

1. Wolfe F., Ross K., Anderson J., et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38 (1995) 19-28
2. Clauw D.J., and Chrousos G.P. Chronic pain and fatigue syndromes: Overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 4 (1997) 134-153
3. Goldenberg D.L., Burckhardt C., and Crofford L. Management of fibromyalgia syndrome. JAMA 292 (2004) 2388-2395
4. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33 (1990) 160-172
5. Abeles A.M., Pillinger M.H., Solitar B.M., and Abeles M. Narrative review: The pathophysiology of fibromyalgia. Ann Intern Med 146 (2007) 726-734
6. Clauw D.J. Fibromyalgia: More than just a musculoskeletal disease. [published correction appears in Am Fam Physician. 1996;54:1896, 1901-1902]. Am Fam Physician 52 (1995) 843-851 853-854
7. Abeles M., Solitar B.M., Pillinger M.H., and Abeles A.M. Update on fibromyalgia therapy. Am J Med 121 (2008) 555-561
8. Goldenberg D.L. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 21 (2007) 499-511
9. Leo R.J., and Brooks V.L. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs 7 (2006) 637-642
10. Vaishnavi S.N., Nemeroff C.B., Plott S.J., et al. Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55 (2004) 320-322
11. Jones C.K., Eastwood B.J., Need A.B., and Shannon H.E. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: Evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology 51 (2006) 1172-1180
12. Obata H., Saito S., Koizuka S., et al. The monoaminemediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 100 (2005) 1406-1410
13. Russell I.J., Vaeroy H., Javors M., and Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 35 (1992) 550-556
14. Stahl S.M. The psychopharmacology of energy and fatigue. J Clin Psychiatry 63 (2002) 7-8
15. Mease P., Arnold L.M., Bennett R., et al. Fibromyalgia syndrome. J Rheumatol 34 (2007) 1415-1425
16. Stahl S.M. Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: Norepinephrine transporters regulate dopamine. J Clin Psychiatry 64 (2003) 4-5
17. Arnold L.M., and Keck Jr. P.E. A meta-analysis and review. Psychosomatics 41 (2000) 104-113
18. Clauw D.J. Fibromyalgia: Update on mechanisms and management. J Clin Rheumatol 13 (2007) 102-109
19. O'Malley P.G., Balden E., Tomkins G., et al. Treatment of fibromyalgia with antidepressants: A meta-analysis. J Gen Intern Med 15 (2000) 659-666
20. Nelson J.C. Tricyclic and tetracyclic drugs. In: Schatzberg A.F., and Nemeroff C.B. (Eds). Textbook of Psychopharmacology. 3rd ed. (2004), American Psychiatric Publishing, Inc, Arlington, Va
21. Puozzo C., Panconi E., and Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 17 Suppl 1 (2002) S25-S35
22. Gendreau R.M., Thorn M.D., Gendreau J.F., et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32 (2005) 1975-1985
23. Harris R.E., Williams D.A., McLean S.A., et al. Characterization and consequences of pain variability in individuals with fibromyalgia. Arthritis Rheum 52 (2005) 3670-3674
24. Dionne R.A., Bartoshuk L., Mogil J., and Witter J. Individual responder analyses for pain: Does one pain scale fit all?. Trends Pharmacol Sci. 26 (2005) 125-130
25. Dworkin R.H., Turk D.C., Wyrwich K.W., et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9 (2008) 105-121
26. Burckhardt C.S., Clark S.R., and Bennett R.M. The Fibromyalgia Impact Questionnaire: Development and validation. J Rheumatol 18 (1991) 728-733
27. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20 (1998) 22-33
28. Beck A.T., Ward C.H., Mendelson M., et al. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
29. US Food and Drug Administration. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance.
30. (October 24, 2008). http://www.fda.gov/cder/guidance/959fnl.pdf Accessed
31. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.
32. (October 24, 2008). http://www.wma.net/e/policy/pdf/17c.pdf Accessed
33. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
34. Hays R.D., and Stewart A.L. Sleep measures. In: Stewart A.L., and Ware Jr. J.E. (Eds). Measuring Functioning and Well-Being: The Medical Outcomes Study Approach (1992), Duke University Press, Durham, NC 235-259
35. Hays R.D., Martin S.A., Sesti A.M., and Spritzer K.L. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 6 (2005) 41-644
36. Seidenberg M., Haltiner A., Taylor M.A., et al. Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol 16 (1994) 93-104
37. Pincus T., Swearingen C., and Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 42 (1999) 2220-2230
38. Smets E.M., Garssen B., Bonke B., and De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39 (1995) 315-325
39. McGahuey C.A., Gelenberg A.J., Laukes C.A., et al. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J Sex Marital Ther 26 (2000) 25-40
40. In: Rao C.R., Miller J.P., and Rao D.C. (Eds). Handbook of Statistics, 27: Epidemiology and Medical Statistics (2008) Amsterdam, The Netherlands: North Holland
41. Ali M.W., and Talukder E. Analysis of longitudinal binary data with missing data due to dropouts. J Biopharm Stat 15 (2005) 993-1007
42. Yunus M.B., Dailey J.W., Aldag J.C., et al. Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol 19 (1992) 90-94
43. Briley M., Prost J.F., and Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 11 Suppl 4 (1996) 9-14
44. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 32 (2000) 305-316
45. Arnold L.M. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 8 Suppl 2 (2007) S63-S74
46. Giesecke T., Gracely R.H., Williams D.A., et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 52 (2005) 1577-1584
47. Gracely R.H., Petzke F., Wolf J.M., and Clauw D.J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46 (2002) 1333-1343
48. Cook D.B., Lange G., Ciccone D.S., et al. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 31 (2004) 364-378
49. Kop W.J., Lyden A., Berlin A.A., et al. Ambulatory monitoring of physical activity and symptoms in fibromyalgia and chronic fatigue syndrome. Arthritis Rheum 52 (2005) 296-303
50. Gahimer J., Wernicke J., Yalcin I., et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 23 (2007) 175-184
51. Clauw D.J. Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry 69 Suppl 2 (2008) 25-29
52. Thompson D., Lettich L., and Takeshita J. Fibromyalgia: An overview. Curr Psychiatry Rep 5 (2003) 211-217
53. Goldenberg D., Clauw D.J., Palmer R.H., et al. One-year durability of response to milnacipran treatment for fibromyalgia. Arthritis Rheum. 56 Suppl 9 (2007) S603 Abstract 1526
54. Buskila D., Sarzi-Puttini P., and Ablin J.N. The genetics of fibromyalgia syndrome. Pharmacogenomics 8 (2007) 67-74
55. Arnold L.M., Hudson J.I., Hess E.V., et al. Family study of fibromyalgia. Arthritis Rheum 50 (2004) 944-952